Medpace (MEDP) Stock Forecast, Price Target & Predictions
MEDP Stock Forecast
Medpace stock forecast is as follows: an average price target of $369.67 (represents a 6.90% upside from MEDP’s last price of $345.81) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.
MEDP Price Target
The average price target for Medpace (MEDP) is $369.67 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $415.00 to $345.00. This represents a potential 6.90% upside from MEDP's last price of $345.81.
MEDP Analyst Ratings
According to 11 Wall Street analysts, Medpace's rating consensus is 'Hold'. The analyst rating breakdown for MEDP stock is 0 'Strong Buy' (0.00%), 5 'Buy' (45.45%), 6 'Hold' (54.55%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Medpace Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Eric Coldwell | Robert W. Baird | $349.00 | $326.54 | 6.88% | 0.92% |
| Sep 25, 2024 | David Windley | Jefferies | $345.00 | $355.82 | -3.04% | -0.23% |
| Aug 01, 2024 | Jailendra Singh | Truist Financial | $415.00 | $382.52 | 8.49% | 20.01% |
| Jul 08, 2024 | Eric Coldwell | Robert W. Baird | $469.00 | $404.13 | 16.05% | 35.62% |
| Jun 13, 2024 | Eric Coldwell | Robert W. Baird | $456.00 | $403.74 | 12.94% | 31.86% |
| May 28, 2024 | Ann Hynes | Mizuho Securities | $435.00 | $390.55 | 11.38% | 25.79% |
| Apr 23, 2024 | David Windley | Jefferies | $450.00 | $376.26 | 19.60% | 30.13% |
| Feb 15, 2024 | John Sourbeer | UBS | $452.00 | $394.34 | 14.62% | 30.71% |
The latest Medpace stock forecast, released on Oct 23, 2024 by Eric Coldwell from Robert W. Baird, set a price target of $349.00, which represents a 6.88% increase from the stock price at the time of the forecast ($326.54), and a 0.92% increase from MEDP last price ($345.81).
Medpace Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 8 |
| Avg Price Target | - | - | $421.38 |
| Last Closing Price | $345.81 | $345.81 | $345.81 |
| Upside/Downside | -100.00% | -100.00% | 21.85% |
In the current month, the average price target of Medpace stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Medpace's last price of $345.81. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 27, 2024 | UBS | Buy | Neutral | Downgrade |
| Sep 25, 2024 | Jefferies | Buy | Hold | Downgrade |
| May 29, 2024 | Cowen & Co. | Buy | Initialise | |
| Apr 23, 2024 | Jefferies | Buy | Upgrade | |
| Feb 15, 2024 | UBS | Neutral | Buy | Upgrade |
| Oct 24, 2023 | Barclays | Outperform | Upgrade | |
| May 08, 2023 | Guggenheim | Neutral | Buy | Upgrade |
| Oct 27, 2022 | RBC Capital | Sector Perform | Downgrade | |
| Oct 27, 2022 | Goldman Sachs | Sector Weight | Downgrade | |
| Oct 27, 2022 | Keefe, Bruyette & Woods | Market Perform | Downgrade | |
| Oct 27, 2022 | Raymond James | Outperform | Upgrade | |
| Oct 27, 2022 | HSBC | Buy | Upgrade | |
| Oct 27, 2022 | UBS | Neutral | Upgrade | |
| Apr 25, 2022 | Zacks Investment Research | Hold | Downgrade |
Medpace's last stock rating was published by Cowen & Co. on Oct 22, 2024. The company gave MEDP a "Buy" rating, the same as its previous rate.
Medpace Financial Forecast
Medpace Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $460.87M | $434.07M | $394.10M | $383.74M | $351.21M | $330.95M | $308.55M | $295.57M | $278.29M | $259.96M | $259.68M | $230.37M | $205.00M | $230.88M | $229.89M | $216.24M |
| Avg Forecast | $641.51M | $624.09M | $606.20M | $584.78M | $569.43M | $556.26M | $545.49M | $535.29M | $534.84M | $540.99M | $528.40M | $512.39M | $498.72M | $475.79M | $433.75M | $401.80M | $386.01M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| High Forecast | $656.32M | $638.49M | $620.19M | $598.28M | $582.57M | $569.11M | $558.09M | $537.77M | $536.73M | $541.71M | $528.41M | $512.39M | $510.23M | $476.71M | $443.77M | $411.08M | $392.55M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| Low Forecast | $630.54M | $613.42M | $595.84M | $574.78M | $559.69M | $546.76M | $536.17M | $532.81M | $531.77M | $540.28M | $528.40M | $512.39M | $490.19M | $474.56M | $426.34M | $394.94M | $381.50M | $357.17M | $344.01M | $327.09M | $309.04M | $291.56M | $272.10M | $265.29M | $245.96M | $218.58M | $182.50M | $226.32M | $222.37M | $217.15M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.08% | 1.02% | 1.07% | 1.02% | 1.01% | 1.00% | 1.01% | 1.02% | 0.98% | 1.06% | 1.05% | 1.12% | 1.02% | 1.03% | 1.00% |
Medpace's average Quarter revenue forecast for Sep 23 based on 5 analysts is $475.79M, with a low forecast of $474.56M, and a high forecast of $476.71M. MEDP's average Quarter revenue forecast represents a 3.24% increase compared to the company's last Quarter revenue of $460.87M (Jun 23).
Medpace EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.63M | $92.16M | $82.33M | $89.27M | $68.09M | $69.31M | $60.32M | $59.05M | $47.68M | $52.69M | $60.47M | $51.36M | $34.78M | $39.95M | $41.15M | $34.77M |
| Avg Forecast | $124.11M | $120.74M | $117.28M | $113.14M | $110.17M | $107.62M | $105.54M | $103.56M | $103.47M | $104.67M | $102.23M | $56.18M | $96.49M | $92.05M | $83.92M | $51.07M | $63.77M | $69.17M | $66.63M | $46.43M | $59.85M | $56.47M | $52.70M | $46.10M | $47.64M | $42.33M | $35.35M | $40.38M | $43.07M | $42.06M |
| High Forecast | $126.98M | $123.53M | $119.99M | $115.75M | $112.71M | $110.11M | $107.97M | $104.04M | $103.84M | $104.80M | $102.23M | $67.42M | $98.71M | $92.23M | $85.86M | $61.29M | $76.52M | $69.17M | $66.63M | $55.72M | $59.85M | $56.47M | $52.70M | $55.31M | $47.64M | $42.33M | $35.35M | $48.46M | $43.07M | $42.06M |
| Low Forecast | $121.99M | $118.68M | $115.28M | $111.20M | $108.28M | $105.78M | $103.73M | $103.08M | $102.88M | $104.53M | $102.23M | $44.95M | $94.84M | $91.81M | $82.48M | $40.86M | $51.01M | $69.17M | $66.63M | $37.15M | $59.85M | $56.47M | $52.70M | $36.88M | $47.64M | $42.33M | $35.35M | $32.31M | $43.07M | $42.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.80% | 1.29% | 1.29% | 1.02% | 1.49% | 1.01% | 1.05% | 0.90% | 1.14% | 1.27% | 1.21% | 0.98% | 0.99% | 0.96% | 0.83% |
5 analysts predict MEDP's average Quarter EBITDA for Sep 23 to be $92.05M, with a high of $92.23M and a low of $91.81M. This is 10.07% upper than Medpace's previous annual EBITDA (Jun 23) of $83.63M.
Medpace Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $61.07M | $72.89M | $68.67M | $66.03M | $49.36M | $61.31M | $50.03M | $48.57M | $39.93M | $43.31M | $50.87M | $41.46M | $24.10M | $28.95M | $29.81M | $23.98M |
| Avg Forecast | $118.92M | $114.62M | $111.42M | $111.15M | $104.10M | $101.57M | $97.29M | $96.11M | $94.31M | $88.90M | $81.46M | $48.87M | $71.26M | $65.66M | $61.43M | $44.43M | $51.96M | $47.31M | $42.10M | $40.39M | $40.11M | $34.65M | $31.76M | $37.24M | $39.79M | $34.44M | $12.72M | $28.57M | $24.22M | $22.89M |
| High Forecast | $122.49M | $118.06M | $114.76M | $114.48M | $107.22M | $104.62M | $100.21M | $96.76M | $96.85M | $89.30M | $81.47M | $58.64M | $73.39M | $66.94M | $63.27M | $53.31M | $62.35M | $47.31M | $42.10M | $48.46M | $40.11M | $34.65M | $32.10M | $44.69M | $39.79M | $34.44M | $12.72M | $34.28M | $24.22M | $22.89M |
| Low Forecast | $116.27M | $112.07M | $108.94M | $108.68M | $101.79M | $99.32M | $95.13M | $95.13M | $91.13M | $88.51M | $81.45M | $39.10M | $69.67M | $64.06M | $60.06M | $35.54M | $41.56M | $47.31M | $42.10M | $32.31M | $40.11M | $34.65M | $31.41M | $29.79M | $39.79M | $34.44M | $12.72M | $22.85M | $24.22M | $22.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.64% | 1.32% | 1.40% | 1.17% | 1.52% | 1.25% | 1.40% | 1.26% | 1.16% | 1.28% | 1.20% | 1.89% | 1.01% | 1.23% | 1.05% |
Medpace's average Quarter net income forecast for Sep 23 is $65.66M, with a range of $64.06M to $66.94M. MEDP's average Quarter net income forecast represents a 7.52% increase compared to the company's last Quarter net income of $61.07M (Jun 23).
Medpace SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.40M | $38.03M | $33.40M | $35.42M | $33.22M | $29.37M | $27.66M | $28.05M | $26.97M | $25.74M | $22.38M | $22.80M | $21.86M | $25.12M | $21.26M | $29.12M |
| Avg Forecast | $61.66M | $59.99M | $58.27M | $56.21M | $54.74M | $53.47M | $52.44M | $51.45M | $51.41M | $52.00M | $50.79M | $23.41M | $47.94M | $45.74M | $41.69M | $21.28M | $28.73M | $34.33M | $33.07M | $19.34M | $29.71M | $28.03M | $26.16M | $22.13M | $23.64M | $21.01M | $17.54M | $29.18M | $21.38M | $20.87M |
| High Forecast | $63.09M | $61.37M | $59.62M | $57.51M | $56.00M | $54.71M | $53.65M | $51.69M | $51.59M | $52.07M | $50.79M | $28.09M | $49.05M | $45.82M | $42.66M | $25.53M | $34.47M | $34.33M | $33.07M | $23.21M | $29.71M | $28.03M | $26.16M | $26.56M | $23.64M | $21.01M | $17.54M | $35.02M | $21.38M | $20.87M |
| Low Forecast | $60.61M | $58.96M | $57.27M | $55.25M | $53.80M | $52.56M | $51.54M | $51.22M | $51.12M | $51.93M | $50.79M | $18.73M | $47.12M | $45.62M | $40.98M | $17.02M | $22.98M | $34.33M | $33.07M | $15.48M | $29.71M | $28.03M | $26.16M | $17.71M | $23.64M | $21.01M | $17.54M | $23.34M | $21.38M | $20.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.79% | 1.16% | 1.03% | 1.00% | 1.52% | 0.93% | 1.00% | 1.03% | 1.16% | 0.95% | 1.08% | 1.25% | 0.86% | 0.99% | 1.40% |
Medpace's average Quarter SG&A projection for Sep 23 is $45.74M, based on 5 Wall Street analysts, with a range of $45.62M to $45.82M. The forecast indicates a 16.07% rise compared to MEDP last annual SG&A of $39.40M (Jun 23).
Medpace EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 1 | 1 | 1 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00 | $2.35 | $2.20 | $2.13 | $1.52 | $1.75 | $1.39 | $1.35 | $1.11 | $1.21 | $1.43 | $1.16 | $0.68 | $0.80 | $0.82 | $0.67 |
| Avg Forecast | $3.71 | $3.57 | $3.47 | $3.46 | $3.24 | $3.17 | $3.03 | $3.00 | $2.94 | $2.77 | $2.54 | $2.47 | $2.22 | $2.05 | $1.91 | $1.82 | $1.79 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $0.99 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| High Forecast | $3.82 | $3.68 | $3.58 | $3.57 | $3.34 | $3.26 | $3.12 | $3.02 | $3.02 | $2.78 | $2.54 | $2.47 | $2.29 | $2.09 | $1.97 | $1.87 | $1.87 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $1.00 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| Low Forecast | $3.62 | $3.49 | $3.40 | $3.39 | $3.17 | $3.10 | $2.96 | $2.96 | $2.84 | $2.76 | $2.54 | $2.47 | $2.17 | $2.00 | $1.87 | $1.77 | $1.70 | $1.47 | $1.31 | $1.26 | $1.25 | $1.08 | $0.98 | $1.00 | $1.24 | $1.07 | $0.40 | $0.74 | $0.76 | $0.71 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.29% | 1.23% | 1.44% | 1.16% | 1.39% | 1.11% | 1.25% | 1.12% | 1.20% | 1.15% | 1.08% | 1.72% | 1.08% | 1.09% | 0.94% |
According to 5 Wall Street analysts, Medpace's projected average Quarter EPS for Sep 23 is $2.05, with a low estimate of $2.00 and a high estimate of $2.09. This represents a 2.31% increase compared to MEDP previous annual EPS of $2.00 (Jun 23).
Medpace Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ICLR | ICON Public | $202.19 | $337.00 | 66.67% | Buy |
| NEOG | Neogen | $11.54 | $17.50 | 51.65% | Buy |
| CRL | Charles River Laboratories | $163.64 | $201.50 | 23.14% | Buy |
| IQV | IQVIA | $203.43 | $249.63 | 22.71% | Buy |
| IDXX | IDEXX Laboratories | $417.86 | $479.75 | 14.81% | Buy |
| QGEN | Qiagen | $45.14 | $49.00 | 8.55% | Buy |
| MEDP | Medpace | $345.81 | $369.67 | 6.90% | Hold |
| MTD | Mettler-Toledo | $1.35K | $1.41K | 4.41% | Hold |
| LH | Laboratory Corporation of America | $248.51 | $258.20 | 3.90% | Buy |
| RVTY | Revvity | $125.59 | $129.44 | 3.07% | Buy |
| WAT | Waters | $413.48 | $371.00 | -10.27% | Buy |
| TWST | Twist Bioscience | $51.86 | $46.00 | -11.30% | Buy |